Trial Profile
Prospective study to investigate the risk of obstructive sleep apnea (OSA) in age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, non-responsive to bevacizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Age-related macular degeneration; Diabetic macular oedema
- Focus Adverse reactions
- 10 Dec 2015 New trial record